Molecular Partners AG Advances Phase 1/2a Trial of Multi-Specific T Cell Engager MP0533
I'm PortAI, I can summarize articles.
Molecular Partners AG has announced the initiation of a Phase 1/2a trial for its multi-specific T cell engager MP0533, with updates expected in the first half of 2026. The company is also advancing its lead Radio-DARPin candidate MP0712, with first patient dosing anticipated in Q1 2026 and data presentations scheduled for January 2026. Additionally, a Phase 2 trial of MP0317 is ongoing for cholangiocarcinoma patients. This information is generated by AI and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments